Gilead Sciences
GILD
1,725 hedge funds and large institutions have $76.2B invested in Gilead Sciences in 2024 Q1 according to their latest regulatory filings, with 139 funds opening new positions, 641 increasing their positions, 734 reducing their positions, and 168 closing their positions.
6% more call options, than puts
Call options by funds: $728M | Put options by funds: $684M
0.88% less ownership
Funds ownership: 84.46% → 83.59% (-0.88%)
3% less funds holding
Funds holding: 1,779 → 1,725 (-54)
11% less capital invested
Capital invested by funds: $85.3B → $76.2B (-$9.06B)
13% less repeat investments, than reductions
Existing positions increased: 641 | Existing positions reduced: 734
17% less first-time investments, than exits
New positions opened: 139 | Existing positions closed: 168
42% less funds holding in top 10
Funds holding in top 10: 24 → 14 (-10)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$378M |
| 2 |
Two Sigma Advisers
New York
|
+$301M |
| 3 |
Voloridge Investment Management
Jupiter,
Florida
|
+$270M |
| 4 |
Two Sigma Investments
New York
|
+$244M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$224M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Parnassus Investments
San Francisco,
California
|
-$809M |
| 2 |
Neuberger Berman Group
New York
|
-$782M |
| 3 |
Goldman Sachs
New York
|
-$342M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$270M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$256M |
GILD Hedge Fund Activity: Q1 2024 in Review
1,725 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q1 2024, worth a combined $76.2B — down 11% from $85.3B a quarter earlier.
Sellers outnumbered buyers: 168 funds closed out of GILD and 139 opened new positions — a net loss of 29 holders — while 734 trimmed existing stakes and 641 added.
The largest buyer was Citadel Advisors, adding an estimated $378M. The largest seller was Parnassus Investments, cutting an estimated $809M.
- 1,725 institutional investors held Gilead Sciences (GILD) as of Q1 2024, down from 1,779 in Q4 2023.
- Funds reported $76.2B of Gilead Sciences stock for Q1 2024, down 11% quarter-over-quarter.
- 139 funds opened new Gilead Sciences positions in Q1 2024 and 168 closed out, a net change of -29 holders.
- The largest Gilead Sciences buyer in Q1 2024 was Citadel Advisors, an estimated $378M added.
- The largest Gilead Sciences seller in Q1 2024 was Parnassus Investments, an estimated $809M sold.
Based on aggregated 13F filings for Q1 2024.